Darrell Wilson

Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital, Emeritus

Clinical Focus

Endocrinology/Diabetes, Pediatric
Pediatrics

Academic Appointments

Professor Emeritus, Pediatrics - Endocrinology and Diabetes
Member, Bio-X
Member, Maternal & Child Health Research Institute (MCHRI)

Administrative Appointments

Member, Stanford Diabetes Research Center (2017 - Present)
Chief, Division of Pediatric Endocrinology and Diabetes (2004 - 2015)

Honors & Awards

See CV at this site, See CV at this site (present)

Profesional Education

Fellowship: Stanford University School of Medicine (1984) CA
Residency: Stanford University School of Medicine (1980) CA
Board Certification: American Board of Pediatrics, Pediatric Endocrinology (1995)
Board Certification, American Board of Pediatrics, Pediatrics (1982)
Board Certification, American Board of Pediatrics, Pediatric Endocrinology (1995)
Internship: Stanford University School of Medicine (1978) CA
Medical Education: UCSD Medical Center (1977) CA

Patents

Bruce Buckingham, Darrell Wilson. "United States Patent 14/175,020 Kalman Filter Based On-Off Switch for Insulin Pump", Stanford

Contact

Academic dwilson@stanford.edu Tel: (650) 721-1811 Fax: (650) 725-8375

Clinical 453 Quarry Rd MC 5660 Stanford CA 94304 Tel: (650) 721-1811 Fax: (650) 725-8375

Current Research and Scholarly Interests

My research interests cover a number of areas in Pediatric Endocrinology and Diabetes. I am PI of the Stanford Center for the NIH-funded Type-1 Diabetes TrialNet group. TrialNet conducts clinical trials directed at preventing or delaying the onset of Type 1 diabetes. I am an investigator in DirecNet, another NIH-funded study group, which is devoted to evaluating glucose sensors and the role of technology on the management of diabetes.

Clinical Trials

Glycemic Control and the Brain in Children With Type 1 Diabetes Recruiting
More
The purpose of this study is to determine if improving diabetes control by better controlling blood sugars, will help improve or normalize brain function as compared to routine diabetes care. We will use either the patient's own insulin routine (injections or insulin pumps) or a closed-loop insulin pump (Medtronic 670G). This system uses a continuous glucose monitor (CGM) and an insulin pump to automatically give insulin and may improve control of blood sugars.
Lead Sponsor
Stanford Investigators
- Tandy Aye
- Darrell Wilson
View full details
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients Recruiting
More
The study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with T1D followed by a 2-year safety follow-up.
Lead Sponsor
Stanford Investigators
- Darrell Wilson
View full details
Comparison of Transdermal and Oral Estrogens in Adolescent Girls With Ovarian Failure Not Recruiting
More
To directly compare the safety (by laboratory evaluation) and efficacy (feminization and growth) of three commonly used estrogen preparations in adolescent patients with ovarian failure, either due to congenital causes (Turner syndrome) or medical therapies. We hypothesize that transdermal estrogen will have equivalent efficacy and a more favorable safety profile in comparison with conventional oral estrogen replacement.

Stanford is currently not accepting patients for this trial. For more information, please contact Sejal Shah, 6507235791.

Lead Sponsor
- Stanford University
Stanford Investigators
- Sejal Shah
- Darrell Wilson
View full details
Pilot Study to Evaluate a Method of Controlling High Blood Sugar in the Pediatric Intensive Care Unit Not Recruiting
More
Recent studies of adult intensive care unit (ICU) patients have shown significantly decreased morbidity and mortality when blood sugar concentrations are closely controlled. The safety and efficacy of this type of blood sugar management has not been studied in the pediatric ICU population. Based on the current pediatric literature data as well as our extensive retrospective study, blood sugar concentrations have a potentially profound role to play among PICU patients. In preparation for a multi-center randomized control trial, we propose a prospective feasibility study to evaluate the safety and effectiveness of using an insulin delivery algorithm to manage blood sugar in the PICU. Our hypothesis for this feasibility trial is that uniformly monitoring and controlling blood glucose with a Discrete-Closed-Loop(DCL) insulin delivery algorithm will be an effective, safe, and consistent means of delivering insulin to manage glucose in the pediatric intensive care unit.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .

Lead Sponsor
- Stanford University
Stanford Investigators
- Bruce Buckingham
- Darrell Wilson
View full details
Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20) Recruiting
More
The study is a 2 arm, multi-center, randomized, open-labeled clinical trial designed to assess the effects of varying doses and schedules of oral insulin on immunological and metabolic markers in relatives at risk for type 1 diabetes (T1D).
Lead Sponsor
Stanford Investigators
- Darrell Wilson
View full details
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Recruiting
More
The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM. Subjects will receive Abatacept or placebo and close monitoring for development of AGT or T1DM. To assess the safety, efficacy, and mode of action of Abatacept to prevent AGT and T1DM. The primary objective is to determine whether intervention with Abatacept will prevent or delay the development of AGT in at-risk autoantibody positive non-diabetic relatives of patients with T1DM. Secondary outcomes include: the effect of Abatacept on the incidence of T1DM; analyses of C-peptide and other measures from the OGTT; safety and tolerability; and mechanistic outcomes.
Lead Sponsor
Stanford Investigators
- Darrell Wilson
View full details
Glaser Obesity Study Not Recruiting
More
This study will determine if the drug metformin, coupled with diet and exercise counseling, will help obese adolescents lose weight.

Stanford is currently not accepting patients for this trial. For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
- Darrell Wilson
View full details
Tocilizumab (TCZ) in New-onset Type 1 Diabetes Recruiting
More
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better glucose control. Researchers believe that tocilizumab could have some effect on the cells in the immune system that are thought to be involved in the development of type 1 diabetes. This study will test whether tocilizumab can help preserve or delay destruction of remaining beta cells in people recently diagnosed type 1 diabetes.
Lead Sponsor
Stanford Investigators
- Darrell Wilson
View full details
TrialNet Pathway to Prevention of T1D Recruiting
More
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM). Genetic and immunologic factors play a key role in the development of T1DM, and characterization of the early metabolic abnormalities in T1DM is steadily increasing. However, information regarding the natural history of T1DM remains incomplete. The TrialNet Natural History Study of the Development of T1DM (Pathway to Prevention Study) has been designed to clarify this picture, and in so doing, will contribute to the development and implementation of studies aimed at prevention of and early treatment in T1DM. Purpose: TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Sweden, Australia, and New Zealand. TrialNet is dedicated to testing new approaches to the prevention of and early intervention for type 1 diabetes. The goal of the TrialNet Natural History Study of the Development of Type 1 Diabetes is to enhance our understanding of the demographic, immunologic, and metabolic characteristics of individuals at risk for developing type 1 diabetes. The Natural History Study will screen relatives of people with type 1 diabetes to identify those at risk for developing the disease. Relatives of people with type 1 diabetes have about a 5% percent chance of being positive for the antibodies associated with diabetes. TrialNet will identify adults and children at risk for developing diabetes by testing for the presence of these antibodies in the blood. A positive antibody test is an early indication that damage to insulin-secreting cells may have begun. If this test is positive, additional testing will be offered to determine the likelihood that a person may develop diabetes. Individuals with antibodies will be offered the opportunity for further testing to determine their risk of developing diabetes over the next 5 years and to receive close monitoring for the development of diabetes.
Lead Sponsor
Stanford Investigators
- Darrell Wilson
View full details
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk" Recruiting
More
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease. Teplizumab has been studied in new onset type 1 diabetes for testing of efficacy and safety in previous studies; other studies are currently in progress. The results of previous studies indicate that teplizumab reduces the loss of insulin production during the first year after diagnosis in individuals with type 1 diabetes. The purpose of this study is to determine if teplizumab can interdict the immune process that causes the destruction of insulin secreting beta cells in the pancreas during the "pre-diabetic" state and thereby prevent or delay the onset of type 1 diabetes.
Lead Sponsor
Stanford Investigators
- Darrell Wilson
View full details
Medtronic Treat to Range (TTR) Closed-Loop Control Not Recruiting
More
The purpose of this study is to evaluate a treat-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes.

Stanford is currently not accepting patients for this trial. For more information, please contact Kari Benassi, RN, FNP, 650-736-8948.

Lead Sponsor
- Stanford University
Stanford Investigators
- Bruce Buckingham
- Darrell Wilson
View full details
Rituximab in New Onset Type 1 Diabetes Not Recruiting
More
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Without these beta cells, the body cannot maintain proper blood glucose levels in response to daily activities such as eating or exercise. With fewer insulin producing cells blood glucose increases, causing hunger, thirst, and unexplained weight loss. By the time these symptoms develop, 80-90% of a person's beta cells have already been destroyed. However, this also means that between 10-20% of these cells remain that continue to produce insulin. Scientists have learned that two types of immune cells, B cells and T cells, are involved in causing type 1 diabetes. T cells are responsible for attacking and destroying the beta cells that make insulin. Although they don't attack insulin producing cells, B cells may be what trigger the T cells to attack. This study will investigate the use of rituximab to see if it can help lower the number of immune B cells thereby preventing the destruction of any remaining insulin producing beta cells that remain at diagnosis. Rituximab is approved by the Food and Drug Administration (FDA) for the treatment of a condition called B-lymphocyte lymphoma. Its effects on the immune system are well understood through its use in organ transplantation. Research has shown that rituximab might be helpful in treating other conditions caused by T cells and B cells, including type 1 diabetes. The goal of this study is to find out if rituximab can preserve residual insulin secretion and prevent further beta cell destruction in type 1 diabetes.

Stanford is currently not accepting patients for this trial. For more information, please contact Allison Rigby, 8772325182.
Lead Sponsor
Stanford Investigators
- Darrell Wilson
View full details
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus Recruiting
More
Type 1 diabetes (T1D) is an autoimmune disease. This means that the immune system (the part of the body which helps fight infections) mistakenly attacks and destroys the cells that produce insulin (islet cells found in the pancreas). As these cells are destroyed, the body's ability to produce insulin decreases. There is evidence suggesting that repeated oral administration of an autoantigen (the same protein that the immune system is reacting to) may introduce a protective immunity and cause the immune system to stop its attack. An earlier, large scale study was done to see if oral insulin could delay or prevent the development of Type 1 diabetes in relatives at risk for developing Type 1 diabetes. The overall results showed that for the entire study population, oral insulin did not delay or prevent Type 1 diabetes. However, an analysis that was done after the conclusion of the trial suggested a potential beneficial effect in a subgroup of participants. The participants who seemed to benefit from oral insulin had higher levels of insulin autoantibodies which are directed against insulin itself ( called mIAA). The Type 1 Diabetes TrialNet study group will further explore the potential role of oral insulin to delay or prevent Type 1 diabetes in a similar group of people. The study will also include a secondary group of individuals at different levels of risk than those in the primary cohort to gather information for future studies.
Lead Sponsor
Stanford Investigators
- Darrell Wilson
View full details
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus Not Recruiting
More
Type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when T cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas. Although it is known that T cells are important mediators of the disease, progress in the development of reliable T cell assays has been modest. The purpose of this study is to learn which T cell assays are most reliable and reproducible so that the investigators can improve their understanding about how type 1 diabetes occurs.

Stanford is currently not accepting patients for this trial. For more information, please contact Alison Rigby, 8772325182.
Lead Sponsor
Stanford Investigators
- Darrell Wilson
View full details

2021-22 Courses

Independent Studies
- Directed Reading in Pediatrics
  PEDS 299 (Aut, Win, Spr, Sum)
- Early Clinical Experience
  PEDS 280 (Aut, Win, Spr, Sum)
- Graduate Research
  PEDS 399 (Aut, Win, Spr, Sum)
- Medical Scholars Research
  PEDS 370 (Aut, Win, Spr, Sum)
- Undergraduate Directed Reading/Research
  PEDS 199 (Aut, Win, Spr, Sum)

Find a doctor

Clinics & Services

Research Resources

Professional Training

Education Resources

Darrell Wilson

Professor of Pediatrics (Endocrinology) at the Lucile Salter Packard Children's Hospital, Emeritus

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

Lead Sponsor

Stanford Investigators

Stanford Investigators

Stanford Investigators

Stanford Investigators

2021-22 Courses